期刊文献+

中性粒细胞明胶酶相关载脂蛋白对急性心肌梗死患者造影剂肾病的预测价值 被引量:6

下载PDF
导出
摘要 目的探讨中性粒细胞明胶酶相关载脂蛋白(neutrophil gelatinase-associated lipocalin,NGAL)对急性心肌梗死患者经皮冠状动脉介入治疗术后造影剂肾病(contrast-induced nephropathy,CIN)的早期预测价值。方法入选直接经皮冠状动脉介入治疗术后的急性心肌梗死患者共101例,分为造影剂肾病组(n=28)及非造影剂肾病组(n=73)。所有入选患者取术前及术后不同时间段静脉血分别用酶联免疫吸附法及碱性苦味酸法测定NGAL浓度及肌酐(creatinine,Cr)浓度。结果造影剂肾病组患者的血清NGAL浓度术后1 h即开始增高[(157.15±12.62)ng/L],术后[(25.0±10.3)h]达峰值[(230.15±10.62)ng/l];血清Cr浓度在术后4 h开始升高,术后[(36.0±11.2)h]峰值出现,血清NGAL、Cr两者浓度时间变化相比差异均有统计学意义(P<0.05)。非造影剂肾病组各时段血清NGAL及Cr无明显变化,与造影剂肾病组比较差异有统计学意义(P<0.05)。选取2 h血清NGAL浓度100 ng/mL为临界点,计算受试工作者特征计算曲线(receive operating characteristic curve,ROC曲线)下面积值为0.92,血清NGAL预测CIN的敏感度为89%和特异度87%。结论 NGAL是急性心肌梗死患者造影剂肾病的早期血清标记物之一。
出处 《广东医学》 CAS CSCD 北大核心 2014年第1期102-105,共4页 Guangdong Medical Journal
  • 相关文献

参考文献13

  • 1GUASTONI C,DE SERVI S. Pathophysiology of contrast-induced nephropathy[J].Giornale Italiano di Cardiologia,2009,(02):73-78.
  • 2PANNU N,WIEBE N,TONELLI M. Prophylaxis strategies for contrast-induced nephropathy[J].Journal of the American Medical Association,2006,(230):2765-2779.
  • 3TOPRAK O,CIRIT M,YESIL M. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease[J].Nephrology Dialysis Transplantation,2007,(03):819-826.
  • 4RAHMAN M M,HAQUE H S,BANERJEE S K. Contrast induced nephropathy in diabetic and non-diabetic patients during coronary angiogram and angioplasty[J].Mymensingh Medical Journal,2010,(03):372-376.
  • 5ELBASAN Z SAHIN D Y,GR M. Contrast-Induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention[J].ANGIOLOGY,2014,(01):37-42.
  • 6PISKINPASA S,ALTUN B,AKOGLU H. An Uninvestigated Risk Factor for Contrast-Induced Nephropathy in Chronic Kidney Disease:Proteinuria[J].Renal Failure,2013,(01):62-65.
  • 7MA G,YU D,CAI Z. Contrast-induced nephropathy in postmenopausal women undergoing percutaneous coronary intervention for acute myocardial infarction[J].Tohoku Journal of Experimental medicine,2010,(03):211-219.
  • 8WICKENBROCK I,PERINGS C,MAAGH P. Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome:differences in STEMI and NSTEMI[J].CLINICAL RESEARCH IN CARDIOLOGY,2009,(12):765-772.
  • 9FU N,LI X,YANG S. Risk Score for the Prediction of Contrast-Induced Nephropathy in Elderly Patients Undergoing Percutaneous Coronary Intervention[J].ANGIOLOGY,2013,(03):188-194.
  • 10COWLAND J B,SORENSEN O E,SEHESTED M. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta,but not by TNF-alpha[J].Journal of Immunology,2003,(12):6630-6639.

同被引文献69

  • 1Schilcher G,Ribitsch W,Otto R,et al.Early detection and intervention using neutrophil gelatinase-associated lipocalin(NGAL)may improve renal outcome of acute contrast media induced nephropathy:a randomized controlled trial in patients undergoing intra-arterial angiography(ANTI-CIN Study)[J].BMC Nephrology 2011 12:39.
  • 2Victor SM, Gnanaraj A, VijayaKumar S, et al. Risk scoring system to predict contrast induced nephrop- athy following percutaneous coronary intervention [J]. Indian Heart J, 2014, 66(5): 517 -524.
  • 3Sanei H, Hajian-Nejad A, Sajjadieh-Kajouei A, et al Short term high dose atorvastatin for the prevention of contrast-induced nephropathy in patients under- going computed tomography angiography [ J ]. ARYA Atheroscler, 2014, 10(5) : 252 -258.
  • 4Sadat U, Usman A, Boyle JR, et al. Contrast me- dium-induced acute kidney injury [ J ]. Cardiorenal Med, 2015, 5(3) : 219 -228.
  • 5Solomon R J, Mehran R, Natarajan MK, et al.Contrast-induced nephropathy and long-term ad- verse events: cause and effect? ~ J 1. Clin J Am Soc Nephrol, 2009, 4(7) : 1162 -1169.
  • 6Liu JM, Xie YN, Gao ZH, et al. Brain natriuretic peptide for prevention of contrast-induced ne- phropathy after percutaneous coronary interven- tion or coronary angiographyE Jl. Can J Cardiol, 2014, 30(12) : 1607 -1612.
  • 7Stacul F, Vander Molen AJ, Reimer P, et al. Con- trast induced nephropathy: updated ESUR Con- trast Media Safety Committee guidelines E J 1. Eur Radiol, 2011,21 (12): 2527 -2541.
  • 8Lauver DA, Carey EG, Bergin IL, et al. Sildenafil citrate for prophylaxis of nephropathy in an ani- mal model of contrast-induced acute kidney injury [J3. PLoS One, 2014, 9(11): e113598.
  • 9Jo SH, Lee JM, Park J, et al. The impact of re- nin-angiotensin-aldosterone system blockade oncontrast-induced nephropathy: a meta-analysis of 12 studies with 4 493 patients [ J ]. Cardiology, 2015, 130(1 ) : 4 -14.
  • 10Firouzi A, Maadani M, Kiani R, et al. Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percuta- neous coronary intervention EJ ]. Int Urol Nephrol, 2015, 47(3) : 521 -525.

引证文献6

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部